e.l.f. Beauty, Inc. (ELF) is primed for evolution with the beta value of 2.12 – The InvestChronicle

Posted on by

e.l.f. Beauty, Inc. (ELF) is priced at $9.38 after the most recent trading session. At the very opening of the session, the stock price was $9.56 and reached a high price of $10.15, prior to closing the session it reached the value of $9.26. The stock touched a low price of $9.19.

e.l.f. Beauty, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $20.00 on 02/14/20, with the lowest value was $7.58 for the same time period, recorded on 03/19/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, e.l.f. Beauty, Inc. shares are logging -53.10% during the 52-week period from high price, and 23.75% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $7.58 and $20.00.

The companys shares, operating in the sector of consumer goods managed to top a trading volume set approximately around 1.07 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the e.l.f. Beauty, Inc. (ELF) recorded performance in the market was -41.85%, having the revenues showcasing -40.52% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 444.61M, as it employees total of 277 workers.

During the last month, 6 analysts gave the e.l.f. Beauty, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 15.79, with a change in the price was noted -8.39. In a similar fashion, e.l.f. Beauty, Inc. posted a movement of -47.21% for the period of last 100 days, recording 875,342 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for ELF is recording 0.58 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.53.

Raw Stochastic average of e.l.f. Beauty, Inc. in the period of last 50 days is set at 14.49%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 17.34%. In the last 20 days, the companys Stochastic %K was 14.37% and its Stochastic %D was recorded 10.96%.

Bearing in mind the latest performance of e.l.f. Beauty, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -41.85%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -49.02%, alongside a downfall of -7.50% for the period of the last 12 months. The shares increased approximately by 3.44% in the 7-day charts and went up by 10.35% in the period of the last 30 days. Common stock shares were lifted by -40.52% during last recorded quarter.

See the article here:

e.l.f. Beauty, Inc. (ELF) is primed for evolution with the beta value of 2.12 - The InvestChronicle

The evolution of cataclysmic binary systems is cyclical – FREE NEWS

Posted on by

The evolution of cataclysmic binary systems is cyclical in nature throughout their life they constantly change from the state of the binary system to the state of a nova, a new star and a dwarf nova. Then the cycle repeats, scientists from the American Museum of Natural History found out, whose work was published in the journal Nature Astronomy.

Cataclysmic binary systems consist of a star like the Sun, a red dwarf, and a dead white dwarf, which gradually sucks energy and matter from its companion.

In the process of theft, the white dwarf forms a critical mass of hydrogen, which at a certain moment explodes like a super-powerful hydrogen bomb. These explosions highlight the system and temporarily make the white dwarf a million times brighter than the Sun.

In a new study, astronomers compiled a mathematical model that allowed us to track the phases that catastrophic binary systems undergo during evolution. The simulation was supposed to show what stages the red dwarf goes through under the influence of his companion.

Scientists have discovered that cataclysmic binaries do not just alternate through each of four states nova, nova-like, dwarf nova and a separate binary system throughout their lives. Just formed binary files during the first several million years of life alternate only the state of the new and new. Then, over the next 10% of lives, the number of phases increases to three nova, nova-like and dwarf nova. During the remaining almost 90% of life, they continuously cycle through all four states.

Statistically, this means that the systems that we observe are newborn systems. And this is less than about 5% of the total number of binary systems. The vast majority are at the following developmental stages, less noticeable for telescopes therefore, science ignores them.

Michael Shara, lead author of the study

Read the original:

The evolution of cataclysmic binary systems is cyclical - FREE NEWS

Hasbro, Inc. (HAS) is primed for evolution with the beta value of 1.49 – The InvestChronicle

Posted on by

At the end of the latest market close, Hasbro, Inc. (HAS) was valued at $51.87. In that particular session, Stock kicked-off at the price of $55 while reaching the peak value of $63.2 and lowest value recorded on the day was $54.88. The stock current value is $63.11.

Hasbro, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $126.87 on 07/30/19, with the lowest value was $41.33 for the same time period, recorded on 03/18/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Hasbro, Inc. shares are logging -50.26% during the 52-week period from high price, and 52.70% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $41.33 and $126.87.

The companys shares, operating in the sector of consumer goods managed to top a trading volume set approximately around 3.27 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Hasbro, Inc. (HAS) recorded performance in the market was -40.24%, having the revenues showcasing -39.08% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.55B, as it employees total of 5600 workers.

During the last month, 10 analysts gave the Hasbro, Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 93.06, with a change in the price was noted -35.53. In a similar fashion, Hasbro, Inc. posted a movement of -36.02% for the period of last 100 days, recording 1,562,545 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for HAS is recording 1.35 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.35.

Raw Stochastic average of Hasbro, Inc. in the period of last 50 days is set at 31.95%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 50.00%. In the last 20 days, the companys Stochastic %K was 27.62% and its Stochastic %D was recorded 17.38%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -40.24%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -46.55%, alongside a downfall of -24.83% for the period of the last 12 months. The shares increased approximately by 3.81% in the 7-day charts and went up by 34.99% in the period of the last 30 days. Common stock shares were lifted by -39.08% during last recorded quarter.

View original post here:

Hasbro, Inc. (HAS) is primed for evolution with the beta value of 1.49 - The InvestChronicle

Crisis in the Chemistry of Origins – Discovery Institute

Posted on by

Editors note: As an alternative to what you are getting pretty much everywhere else in the media at the moment, Evolution News is proud to offer inspiration, pointing to purpose and meaning in life. The profoundest mystery and thus the deepest inspiration is life itself. Discovery Institute Press has just published a greatly expanded edition of the 1984 classic of intelligent design science literature, The Mystery of Lifes Origin. Below is an excerpt from the original introduction by Charles Thaxton, Walter Bradley, and Roger Olsen.

Two monumental scientific reports appeared in 1953, both of which have subsequently received wide acceptance in the scientific community. One was the proposal by James Watson and Francis Crick of their double helical model for deoxyribonucleic acid, or DNA. According to their now-famous model, hereditary information is transmitted from one generation to the next by means of a simple code resident in the specific sequence of certain constituents of the DNA molecule. It had previously been held that the spectacular diversity of life was due in part to some corresponding diversity of nuclear material. The breakthrough by Crick and Watson was their discovery of the specific key to lifes diversity. It was the extraordinarily complex yet orderly architecture of the DNA molecule. They had discovered that there is in fact a code inscribed in this coil of life, bringing a major advance in our understanding of lifes remarkable structure.

Almost as if synchronized for the sake of irony, the other report in 1953, by Stanley Miller, offered experimental support for what has become an increasingly apparent contradiction. Miller offered his work in support of the neo-Darwinian theory of prebiotic evolution. This notion suggested that the fantastic complexity in the molecular organization of living cells might somehow have resulted from nothing more than simple chemicals interacting at random in a primordial ocean.

In 1953, few if any were troubled by the tension between the new insights of Crick and Watson on the one hand and Millers results on the other. Crick and Watson were concerned with lifes structure and Miller was concerned with lifes origin. Most observers had an unshakable confidence that these two investigative approaches would eventually converge. After all, young Millers announcement of experimental success was just what was anticipated according to the general theory of evolution. Regardless of whether the particular theory of evolution is Darwinian, neo-Darwinian, or something else, an evolutionary preamble to the biological phase of evolution is clearly required. Chemical evolution, then, is the pre-biological phase of evolution in which the very earliest living things came into being. This monumental dawning of life occurred through the variation of natural forces acting on matter over long time spans, perhaps up to a thousand million years, or maybe longer.

In the decades since Millers and Crick and Watsons reports, however, there have been indications that all is not well in the halls of biology. We have gained a far deeper appreciation of the extremely complex macromolecules such as proteins and nucleic acids. The enlarged understanding of these complexities has precipitated new suggestions that the DNA mechanism may be more complex and the molecular organization more intricate and information-filled than was previously thought.

The impressive complexities of proteins, nucleic acids, and other biological molecules are presently developed in nature only in living things. Unless it is assumed such complexity has always been present in an infinitely old universe, there must have been a time in the past when life appeared de novo out of lifeless, inert matter. How can the mere interaction of simple chemicals in the primordial ocean have produced life as it is presently understood? That is the question. The signs do not bode well for the standard answers given, and some investigators are suggesting that our two approaches will not converge.

Read the rest in The Mystery of Lifes Origin: The Continuing Controversy, from Discovery Institute Press.

Photo: (l. to r.) Roger Olsen, Charles Thaxton, and Walter Bradley signing books at the 2020 Dallas Conference on Science & Faith, by Chris Morgan.

Read this article:

Crisis in the Chemistry of Origins - Discovery Institute

Rexnord Corporation (RXN) is primed for evolution with the beta value of 1.15 – The InvestChronicle

Posted on by

Lets start up with the current stock price of Rexnord Corporation (RXN), which is $21.77 to be very precise. The Stock rose vividly during the last session to $22.64 after opening rate of $20.77 while the lowest price it went was recorded $20.52 before closing at $19.54.

Rexnord Corporation had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $35.64 on 02/14/20, with the lowest value was $18.87 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Rexnord Corporation shares are logging -38.92% during the 52-week period from high price, and 15.37% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $18.87 and $35.64.

The companys shares, operating in the sector of industrial goods managed to top a trading volume set approximately around 1.15 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Rexnord Corporation (RXN) recorded performance in the market was -33.26%, having the revenues showcasing -33.73% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.04B, as it employees total of 6700 workers.

During the last month, 6 analysts gave the Rexnord Corporation a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 31.08, with a change in the price was noted -6.72. In a similar fashion, Rexnord Corporation posted a movement of -23.59% for the period of last 100 days, recording 994,548 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for RXN is recording 0.84 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.84.

Raw Stochastic average of Rexnord Corporation in the period of last 50 days is set at 17.29%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.77%. In the last 20 days, the companys Stochastic %K was 9.13% and its Stochastic %D was recorded 12.06%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -33.26%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -21.86%, alongside a downfall of -12.46% for the period of the last 12 months. The shares increased approximately by 1.44% in the 7-day charts and went up by -12.15% in the period of the last 30 days. Common stock shares were lifted by -33.73% during last recorded quarter.

Link:

Rexnord Corporation (RXN) is primed for evolution with the beta value of 1.15 - The InvestChronicle

Global Stem Cell Market: Focus on Clinical Therapies, 2020-2030 (based on Source ; Origin ; Type ; Lineage ; and Potency ) – P&T Community

Posted on by

NEW YORK, March 24, 2020 /PRNewswire/ --

INTRODUCTIONAccording to the WHO, in 2020, nearly 75% of fatalities that are estimated to be reported across the globe, are likely to be caused due to diseases, such as chronic stroke disease, diabetes, cancer, heart disease, and certain mental health conditions. In addition, as per a report published by the Center for Managing Chronic Disease, University of Michigan, more than 50% of the global population was estimated to be living with some form of chronic illness. The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options. Despite advances in healthcare, there is an evident lack of permanent treatment solutions for many aforementioned diseases. Majority of the currently available treatment options focus on palliative care and are incapable of addressing the root cause of disease, therefore, are unable to improve quality of life of patients.

Read the full report: https://www.reportlinker.com/p05877767/?utm_source=PRN

Since the first bone marrow transplant in 1950s, these regenerative cellular therapies have garnered significant attention within the biopharmaceutical industry. Over the years, advances in the field of cell biology and regenerative medicine have led to the development of a number of stem cell therapies, which are believed to possess the potential to address several unmet needs related to the treatment of a wide range of disease conditions. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms. In fact, such interventions have also been shown to enable cell regeneration, restoring normal functioning capabilities in affected organs. Till date, nearly 25 stem cell-based therapies have been approved; popular examples include EYE-01M (2019), Alofisel (2018), MACI (2016), Stempeucel (2016) and Strimvelis (2016). Further, several such therapies are presently being evaluated across 540 active clinical trials worldwide. This emerging field of research has received significant capital investments from several big pharma companies and venture capital funds / investors. Despite the associated optimism, the growth of this market is stunted by a number of development and manufacturing related challenges, primarily revolving around the limited availability of the required expertise and infrastructure to produce such products. However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term.

SCOPE OF THE REPORTThe "Global Stem Cell Market: Focus on Clinical Therapies, 20202030 (based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))" report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromal cells and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. In addition, information on the various technology platforms being actively used for the development of stem cell therapies has been provided. Identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas). Detailed profiles of the key industry players engaged in the development of stem cell-based therapies, featuring a brief overview of the company (such as year of establishment, company size, location of headquarters, key members of the executive team and financial information (if available)), details of their respective product portfolio and an informed future outlook. An assessment of over 20 commonly targeted therapeutic indications and details of stem cell-based therapies being developed to treat the same conditions, highlighting disease specific epidemiological facts, contemporary methods of diagnosis, and currently available treatment options and their side-effects. An analysis of potential growth opportunities for stem cell therapies across different therapeutic areas in the established / emerging regions, based on the Ansoff growth model. An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute, funding institute center, funding institute center, support period, spending categorization, funding mechanism, grant type, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of stem cell (based on origin, source, potency and lineage) and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of indications under investigation. A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials. A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers (such as year of establishment, company size, location of headquarters and manufacturing facilities), scale of stem cell manufacturing (commercial, clinician and preclinical), services offered in addition to manufacturing (culture development / set up, stem cell identification / validation, stem cell banking, regulatory consultancy, fill / finish, cryopreservation and stem cell logistics), source of stem cells (allogeneic and autologous), and origin of stem cells (adult and embryonic), [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner. A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies. An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization (prior to product launch, post-marketing, and near patent expiry), and the key strategies that have been adopted by drug developers for the commercialization of their proprietary product candidates. An analysis of contemporary trends, as observed on the Google Trends portal, for the period 2015-2019 and insights from the recent news articles related to stem cell therapies indicating the increasing popularity of this upcoming field of research.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for stem cell therapies over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved stem cell therapies. The report also features the likely distribution of the current and forecasted opportunity within stem cell therapies market across [A] source of stem cells (allogeneic and autologous), [B] origin of stem cells (adult and embryonic), [C] type of stem cells (hematopoietic, mesenchymal, progenitor and others), [D] lineage of stem cells (adipose tissue, bone marrow and cord blood / embryonic stem cells), [E] route of administration (intraarticular, intracoronary, intramuscular, intramyocardial, intrathecal, intravenous, surgical implantation and others), [F] therapeutic area (autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others), [H] end-users (ambulatory surgery centers, hospitals, and specialty clinics), and [G] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: William L Rust (Founder and Chief Executive Officer, Seraxis) Xuejun Huang Parsons (Chief Executive Officer, Xcelthera) Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem) Kikuo Yasui (Director and Chief Operating Officer, Heartseed) Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock) Gilles Devillers (President, Bio Elpida) Fiona Bellot (Business Development Manager, Roslin Cell Therapies) David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota) Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of stem cell therapies market and their likely evolution in the short-mid term and long term.

Chapter 3 provides a brief introduction to stem cell therapies, highlighting details regarding their development and administration. It includes information on various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of therapy administration and the disease indications targeted by such interventions. It also emphasizes on the challenges related to the development of such therapy candidates. In addition, it provides a detailed description of the regulatory landscape related to stem cell therapies across various geographies, such as the North America (primarily the US), Europe and other key global regions. Further, it includes an analysis of contemporary trends, as observed on the Google Trends portal, for the period 2015-2019 and insights from the recent news articles related to stem cell therapies indicating the increasing popularity of this upcoming field of research.

Chapter 4 includes information on over 280 stem cell-based therapies approved / under clinical development, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), phase of development (marketed, phase III, phase II, phase I), source of stem cells (allogeneic and autologous), origin of stem cells (adult and embryonic), type of stem cells (hematopoietic, mesenchymal, progenitor and others), stem cell lineage (amniotic fluid, adipose tissue, bone marrow, cardiosphere, chondrocytes, corneal tissue, cord blood, dental pulp, neural tissue placenta, peripheral blood, stromal cells and others), stem cell potency (multipotent and pluripotent), target indication(s), key therapeutic area(s), route of administration (intravenous, intramuscular, intraarticular, intramyocardial, intracoronary, intrathecal and others), and information on number of stem cells, special drug / therapy designation (if any), commercial geographical rights. It also focuses on the identification of contemporary market trends, depicted using five schematic representations, which include [A] a tree map representation of the various industry players involved in the development of stem cell therapies, distributed on the basis of the target therapeutic areas of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a schematic world map representation, highlighting the geographical locations of various industry players, [C] a bubble analysis comparing the leading players engaged in the generation of stem cell therapies, on the basis of parameters such as pipeline strength (based on the number of therapy candidates developed by a particular company, across different phases of development), number of target indications and the size of the developer company, [D] an insightful grid analysis, highlighting the distribution of therapy candidates on the basis of phase of development, source of stem cell and target therapeutic areas, and [E] an informative heptagon representation, highlighting the distribution of marketed / clinical stem cell therapies across popular target therapeutic areas (based on the number of therapy candidates across each target therapeutic areas). In addition, information on the various technology platforms being actively used for the development of stem cell therapies, has been provided.

Chapter 5 features detailed profiles of key industry players engaged in the development of stem cell-based therapies (shortlisted on the basis of number of pipeline products). Each profile features a brief overview of the company along with the information on year of establishment, company size, location of headquarters, key members of the executive team and financial information (if available), details on their respective product portfolio, and an informed future outlook.Chapter 6 presents an assessment of over 20 most commonly targeted therapeutic indications and details of stem cell-based therapies being developed to treat them, highlighting disease specific epidemiological facts, contemporary methods of diagnosis, and currently available treatment options and their side-effects.

Chapter 7 highlights an analysis of potential growth opportunities for stem cell therapies across different therapeutic areas in the established / emerging markets, based on the Ansoff growth model.

Chapter 8 provides an analysis of more than 1,500 grants that were awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November) based on the important parameters associated with grants, such as year of grant award, amount awarded, administration institute, funding institute center, funding institute center, support period, spending categorization, funding mechanism, grant type, responsible study section, focus area, prominent program officers, and type of recipient organizations. It also features a detailed analysis based on the types of stem cell (based on origin, source, potency and lineage) and therapeutic areas, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of indications under investigation.

Chapter 9 provides a detailed clinical trial analysis of more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.

Chapter 10 features a review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers (such as year of establishment, company size, location of headquarters and manufacturing facilities), scale of stem cell manufacturing (commercial, clinician and preclinical), services offered in addition to manufacturing (culture development / set up, stem cell identification / validation, stem cell banking, regulatory consultancy, fill / finish, cryopreservation and stem cell logistics), source of stem cells (allogeneic and autologous), and origin of stem cells (adult and embryonic), [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.

Chapter 11 presents a detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.

Chapter 12 features an elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization (prior to product launch, post-marketing, and near patent expiry), and the key strategies that have been adopted by drug developers for the commercialization of their proprietary product candidates.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the stem cell therapy market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] source of stem cells (allogeneic and autologous), [B] origin of stem cells (adult and embryonic), [C] type of stem cells (hematopoietic, mesenchymal, progenitor and others), [D] lineage of stem cells (adipose tissue, bone marrow and cord blood / embryonic stem cells), [E] route of administration (intraarticular, intracoronary, intramuscular, intramyocardial, intrathecal, intravenous, surgical implantation and others), [F] therapeutic area (autoimmune / inflammatory disorders, cardiovascular disorders, metabolic disorders, musculoskeletal disorders, oncological disorders, neurological disorders, ophthalmic disorders, and others), [H] end users (ambulatory surgery centers, hospitals, and specialty clinics), and [G] key geographical regions (North America, Europe and Asia and rest of the world).

Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the stem cell therapy domain. We have inputs from William L Rust (Founder and Chief Executive Officer, Seraxis), Xuejun Huang Parsons (Chief Executive Officer, Xcelthera), Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem), Kikuo Yasui (Director and Chief Operating Officer, Heartseed), Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock), Gilles Devillers (President, Bio Elpida), Fiona Bellot (Business Development Manager, Roslin Cell Therapies), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Read the full report: https://www.reportlinker.com/p05877767/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-stem-cell-market-focus-on-clinical-therapies-20202030-based-on-source--origin--type--lineage--and-potency--301028853.html

SOURCE Reportlinker

Read this article:

Global Stem Cell Market: Focus on Clinical Therapies, 2020-2030 (based on Source ; Origin ; Type ; Lineage ; and Potency ) - P&T Community

Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio – Yahoo…

Posted on by

The global autologous cell therapy market is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200323005764/en/

Technavio has published a latest market research report titled Global Autologous Cell Therapy Market 2020-2024 (Graphic: Business Wire)

Read the 120-page report with TOC on "Autologous Cell Therapy Market Analysis Report by Therapy (Autologous stem cell therapy and Autologous cellular immunotherapies), Application (Oncology, Musculoskeletal disorders, and Dermatology), Geography (North America, APAC, Europe, South America, and MEA), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/autologous-cell-therapy-market-industry-analysis

The market is driven by the increasing demand for effective drugs for cardiac and degenerative disorders. In addition, the limitations in traditional organ transplantations are fueling the demand for stem cell therapies. All these factors are anticipated to boost the growth of the autologous cell therapy market.

The demand for effective drugs for cardiac and degenerative disorders has been increasing across the world. In addition, the discovery of possible cardiac autologous cells has enabled vendors to develop novel drugs for the treatment of various cardiac diseases. For instance, Mesoblast is developing MPC-150-IM. It is a Phase III candidate for the treatment of advanced and end-stage chronic heart failure. Similarly, Shire has been developing autologous stem cell therapies for chronic myocardial ischemia. These products are expected to be launched during the forecast period and will have a positive impact on the growth of the global autologous cell therapy market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Autologous Cell Therapy Market Companies:

Bayer AG

Bayer AG operates its business through segments such as Pharmaceuticals, Crop Science, Consumer Health, and Animal Health. The company offers induced pluripotent stem cells. They are developed by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. operates its business through an unified business segment. NurOwn is the key offering of the company. It is a cell therapy platform, which develops mesenchymal stem cells for the treatment of human diseases such as immune and inflammatory diseases.

Daiichi Sankyo Co. Ltd.

Daiichi Sankyo Co. Ltd. operates its business through segments such as Innovative Pharmaceuticals, Generic, Vaccine, and OTC Related. Heartcel is the key offering of the company. It is an immune-modulatory progenitor cell therapeutic agent, which is used for ischemic heart failure.

FUJIFILM Holdings Corp.

FUJIFILM Holdings Corp. operates its business through segments such as Imaging solutions, Healthcare and material solutions, and Document solutions. The company uses induced pluripotent stem cells to derive differentiated cells, which are used in researching various diseases and conditions.

Story continues

Holostem Terapie Avanzate Srl

Holostem Terapie Avanzate Srl operates its business through an unified business segment. Holoclar is the key offering of the company. It is an advanced therapy medicinal product containing stem cells indicated to repair the cornea after injury.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Autologous Cell Therapy Market Therapy Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Application Outlook (Revenue, USD Billion, 2020-2024)

Autologous Cell Therapy Market Regional Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Related Reports on Healthcare Include:

Global Cancer Stem Cell Therapeutics Market Global cancer stem cell therapy market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

Global Mantle Cell Lymphoma Therapeutics Market Global mantle cell lymphoma therapeutics market by product (combination therapy and monotherapy) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005764/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

Read more here:

Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio - Yahoo...

Can cell-based therapy be helpful in tackling coronavirus? – YourStory

Posted on by

Ever since the novel coronavirus, or COVID-19, was first reported in China's Wuhan city, the virus has spread to more than 196 countries and territories around the world with393,284 confirmed cases and17,161 deaths so far. In India, the maximum number of cases has been reported in the state of Maharashtra.The number of coronavirus cases in the country has risen to 519, with 10 deaths.

It is the need of the hour to find a solution for coronavirus.

Clinical trials in China are already testing the efficacy of stem cell therapies for COVID-19. Arecent clinical trialwith seven COVID-19 patients showed that a stem cell product improved patient outcome. According to research published in the peer-reviewed journalAging and Disease,mesenchymal stem cell (MSC) therapy could be effective in treating COVID-19.

Coronaviruses (CoV) belong to a large family of viruses leading to respiratory illnesses, such as common coldto more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute RespiratorySyndrome (SARS-CoV).

Earlier this year, a new strain of coronavirus was discovered, which was not previously identified in humanbeings, also known as the novel coronavirus (nCov). The symptoms of the infection are respiratory issues, fever, cough, shortness of breath, and breathingdifficulties. More severe cases of COVID-19 can cause pneumonia, severe acute respiratory syndrome, and kidneyfailure.

In recent years, scientific research hasshown that MSCs have properties that maymake them very useful to repair damaged tissues in the patients respiratory system and promotefaster healing and recovery.Umbilical cord tissueis particularly rich inthese cells, which is why many parents arechoosing to store them at birth.

MSCs can reduce the overproduction of immune cells caused by a reaction to the virus and reduce excessive levels of inflammatory substances, thus regulating the immune system.

Currently, many vaccines or drugs are being tested to deal with coronavirus. There is widespread fear and phobia among the population. Why not use your own defence system rather than searching for drugs to tackle the virus?

MSCs are multi-potent cells that have been widely used for tissue regeneration and immunomodulation, and can be a potential solution. The infusion of autologous and allogenic MSCs has been proven safe and effective in tissue repair and disease modulation. MSCs have anti-inflammatory, antimicrobial properties; therefore, they have the potential to control inflammatory conditions, possibly viral diseases, and may reduce mortality.

Another interesting therapeutic avenue is immunotherapy. Natural killer (NK) cells, a component of our innate immune system, play an important role in tackling malignancies as well as virally infected cells. These cells serve to contain viral infections while the adaptive immune response is generating antigen-specific cytotoxic T cells that can clear the infection. Thus, NK cell therapy can be safe and effective in the management of COVID-19.

We need to ensure control of person-to-person transmission of the infection. Therefore, stringent isolation/quarantine measures are important until complete recovery of an infected individual.

(Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the views of YourStory.)

How has the coronavirus outbreak disrupted your life? and how are you dealing with it? Write to us or send us a video with subject line 'Coronavirus Disruption' to editorial@yourstory.com

See the article here:

Can cell-based therapy be helpful in tackling coronavirus? - YourStory

Clinical trial to find effective Covid-19 treatments gets underway – Nursing Times

Posted on by

The first patients have now been recruited for a new UK clinical trial of potential drug treatments for Covid-19.

There are currently no specific treatments for the virus but researchers from the University of Oxford will explore whether any existing medications are effective.

There is an urgent need for reliable evidence on the best care for patients with Covid-19"

Peter Horby

In the first instance, the Randomised Evaluation of Covid-19 Therapy (RECOVERY) trial will look at lopinavir-ritonavir, normally used to treat HIV, and the steroid dexamethasone, which is used in a wide range of conditions to reduce inflammation.

The drugs were recommended for inclusion by an expert panel that advises the chief medical officer in England and in the future it is anticipated that the trial will be expanded to assess the impact of other potential treatments.

The chance to join the trial will be offered to adult inpatients who have tested positive for Covid-19 in NHS hospitals and who have not been excluded for medical reasons.

All participants will receive the usual standard of care and will also be chosen at random to receive one of the two drugs being studied or no additional medication.

This will enable researchers to see whether any of the possible new treatments are more or less effective than those currently used for patients with the new strain of coronavirus.

In this way we can rapidly assess the value of potential treatments for Covid-19"

Martin Landray

Peter Horby, professor of emerging infectious diseases and global health in the Nuffield Department of Medicine, University of Oxford, is chief Investigator for the trial.

He said: There is an urgent need for reliable evidence on the best care for patients with Covid-19.

Providing possible new treatments through a well-designed clinical trial is the best way to get that evidence.

Deputy chief investigator Martin Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health, University of Oxford, added: The streamlined design of this clinical trial allows consenting patients to be enrolled in large numbers easily and without compromising patient safety or adding significantly to the workload of busy hospitals and their staff.

In this way we can rapidly assess the value of potential treatments for Covid-19 and provide reliable information on the best ways to treat patients with this disease.

English chief medical officer Chris Whitty and NHS England medical director Stephen Powis have written to NHS trusts in England asking them to fully support the new trial.

Original post:

Clinical trial to find effective Covid-19 treatments gets underway - Nursing Times

Study Shows Development of Young Cells Could be New Option in Cancer Care – BioSpace

Posted on by

Washington University School of Medicinein St. Louis released a newstudyabout the effectiveness of immunotherapy based on the age of the cells used. The study, published in the journalDevelopmental Cell,showed that these natural killer cells seem to be more effective when they are young. Natural killer (NK) cells, as they're called, are used in immunotherapy to treat cancer using the body's immune cells or immune cells from a matched donor.

"We are trying to improve the effectiveness of immunotherapy for more patients," said senior author Christopher M. Sturgeon, Ph.D., an assistant professor of medicine.

Typically, NK cells used in investigational immunotherapy are adult and come from the patient or donor bone marrow. While these therapies can work, they don't work for everyone.

In contrast, young NK cells do not use the patient's cell or donor cells. These early NK cells, typically formed in the yolk sac in the early embryo, are instead able to be created with human pluripotent stem cells. They can be manufactured quickly by most academic medical centers, thus eliminating the time it takes to process patient's or donor's cells for typical NK cell therapy.

"This special source of natural killer cells has the potential to fill some of the gaps remaining with adult NK cell therapy. There is early evidence that they are more consistent in their effectiveness, and we would not need to process cells from a donor or the patient. They could be manufactured from existing cell supplies following the strict federal guidelines for good manufacturing practices. The characteristics of these cells let us envision a supply of them ready to pull off the shelf whenever a patient needs them," Sturgeon said.

Instudieswith mice using the lab-developed human pluripotent stem cells to create early NK cells, researchers found positive results. These cells were significantly better at degranulation than adult NK cells. Even cells from umbilical cord blood did not respond as well as the early NK cells. Additionally, early NK cells are a particular type of short-lived immune cell, meaning that even if the cells cause harm, they aren't in the body for very long. However, NK cells, in general, do not attack the body's healthy tissues significantly, unlike many T cell therapies.

"Based on their unique behavior alone, there is one small clinical trial of these cells that is ongoing. Now that we know how to manufacture them and how they work, it opens the door for more trials and for improving upon their function, " Sturgeon said.

More research will need to be put into understanding why these special cells only show up in the early embryo and where they go after.

The origin and why they work so well is still a complete mystery.

"We can only speculate at this point, but it's possible that during early embryonic development, when there is so much rapid cell division, these cells are there as a surveillance mechanism to protect against pediatric cancers or infection," he said.

In addition to the early NK cells, pluripotent stem cells also have the potential to bring about many other different cell types, creating more possibilities.

Read more from the original source:

Study Shows Development of Young Cells Could be New Option in Cancer Care - BioSpace

Canine Stem Cell Therapy Market top key players, size, Analysis, growth, research, Types, Regions and Forecast from 2019-2024 – Packaging News 24

Posted on by

The global Canine Stem Cell Therapy market registered a value of ~US$ xx Mn/Bn in 2019 and is spectated to grow at CAGR of xx% during the foreseeable period 2019-2029. In terms of product type, segment holds the largest share, while segment 1 and segment 2 hold significant share in terms of end use.

The Canine Stem Cell Therapy market study outlines the key regions Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2), region 3 (Country 1, Country 2) and region 4 (Country 1, Country 2). All the consumption trends and adoption patterns of the Canine Stem Cell Therapy are covered in the report. Prominent players, including player 1, player 2, player 3 and player 4, among others, account for substantial shares in the global Canine Stem Cell Therapy market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

The Canine Stem Cell Therapy market research answers important questions, including the following:

The Canine Stem Cell Therapy market research serves a platter of the following information:

Why go for Canine Stem Cell Therapy Market Research?

Our analysts work irrespective of the time-zone, the result, we are being recognized worldwide. We abide by the notion that each client has his/her own set of requirements. With extensive primary and secondary research, our experts churn out the most accurate information regarding the desired the Canine Stem Cell Therapy market.

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

Read more:

Canine Stem Cell Therapy Market top key players, size, Analysis, growth, research, Types, Regions and Forecast from 2019-2024 - Packaging News 24

Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position – Seeking Alpha

Posted on by

Introduction

Sangamo Therapeutics (SGMO) is a clinical-stage biotech company focusing on the research and development of genomic medicine across 4 distinct technology platforms: gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation.

Sangamo is best-known for developing its proprietary gene-editing technology, zinc finger proteins ("ZFPs"), which is a naturally occurring class of transcription factor proteins found in humans and other species. The company has used its internal know-how and technical expertise to develop a proprietary synthetic ZFP platform with potential clinical utility in ex vivo gene-edited cell therapy, in vivo genome editing, and in vivo genome regulation.

ZFPs also can be engineered to make zinc finger nucleases ("ZFNs") which proteins that can be used to specifically modify DNA sequences by knocking in or knocking out select genes, or genome editing, and ZFP transcription-factors ("ZFP-TFs") which are proteins that can be used to selectively increase or decrease gene expression.

Sangamo is developing a series of clinical programs, which are either wholly-owned or partnered with well-established pharma and biotech companies, to focus on 3 therapeutics areas in inherited metabolic disease ("IMDs"), central nervous system ("CNS), and inflammatory and autoimmune diseases. Its full list of clinical pipeline programs is listed in Figure 1.

Figure 1 Sangamo Therapeutics' Clinical Pipeline (Source)

The company's most advanced program is an investigational gene therapy for severe hemophilia A, SB-525. SB-525 is developed under a global collaboration with Pfizer (PFE), of which the rights of SB-525 have been transferred to Pfizer to run a phase 3 trial. In December 2019, both companies announced updated initial data from the phase1/2 trial of SB-525. SB-525 was generally well-tolerated and demonstrated a sustained increase in Factor VIII activity. SB-525 has been granted RMAT, Orphan Drug, and Fast Track designation by the FDA as well as Orphan Medicinal Product Designation by the European Medicines Agency ("EMA").

Beyond SB-525, the company is also investigating 2 wholly-owned gene therapy. ST-920 is being evaluated to treat Fabry disease, a rare inherited metabolic disease, in a phase 1 study in the US and UK. SB-920 has received Orphan Drug designation by the FDA. The company also plans to advance ST-101 into clinical trials in 2021 to treat phenylketonuria ("PKU") which is a rare inherited disorder that originates from a defect in the PAH gene and results in a harmful accumulation of phenylalanine in cells throughout the body.

Sangamo is working with Sanofi (NASDAQ:SNY) to develop ex vivo gene-edited cell therapies, ST-400 and BIVV-003, for transfusion-dependent beta-thalassemia ("TDT") and sickle cell disease ("SCD") respectively. Both ST-400 and BIVV-003 are related product candidates using the same technology involving gene editing of a patient's own hematopoietic stem progenitor cells using non-viral delivery of ZFN technology.

Sangamo is the phase 1/2 study of ST-400 in 6 patients with TDT while Sanofi is recruiting the phase1/2 study evaluating BIVV-003 in patients with SCD, and Sanofi is responsible for the subsequent development, manufacturing, and commercialization of both programs.

In Dec 2009, Sangamo presented interim results for the first 3 patients ST-400. As of the data cut date, 2 more patients have been enrolled although they were not included in the interim updates. The 3 patients treated with ST-400 experienced prompt hematopoietic reconstitution, demonstrating neutrophil engraftment in 14-22 days and platelet engraftment in 22-35 days. No emerging clonal hematopoiesis had been observed as measured by on-target indel pattern monitoring in the three treated patients. The downside of the data readout is that its treatment of TDT appears to be not as efficacious as other competitors such as bluebird bio (BLUE).

Sangamo also has a global collaboration and license agreement with Kite Pharma, a wholly-owned subsidiary of Gilead Sciences (GILD), for the development of engineered cell therapies for cancer. The company is working together with Kite to design ZFNs and viral vectors to disrupt and insert select genes in T cells and natural killer cells. The first program of this agreement expected to start a clinical trial in 2020 is KITE-307, which is an allogeneic anti-CD19 CAR-T cell therapy. Given the well-documented struggles of Kite's approved autologous CAR-T, Yescarta, the success of allogeneic CAR-Ts will be very beneficial.

Lastly, Sangamo is also evaluating the potential of regulatory T-cells ("Tregs") genetically modified with a CAR ("CAR-Tregs") in solid organ transplantation. CAR-Treg cell therapies are being conducted in several preclinical studies in autoimmune and inflammatory diseases such as multiple sclerosis ("MS") and inflammatory bowel disease ("IBD"). The most advanced CAR-Treg cell therapy is TX200, which is an autologous treatment for the prevention of solid organ transplant rejection and the clinical trial is expected to be initiated in 2020.

Sangamo is only planning to start a new clinical trial for its in vivo genome editing programs. SB-913 is a second-generation ZFNs program that will be used to treat Mucopolysaccharidosis type II ("MPS II") and a new clinical trial is planned to start this year.

The company had previous programs from first-generation ZFNs that have been halted as they did not demonstrate enough clinical benefits. The company plans to use data from the SB-913 study to definite the next steps for its in vivo genome editing programs.

The company also has several preclinical programs evaluating their ZFP-TF technology as a novel therapeutic approach for CNS diseases. In December, Sangamo announced a collaboration with Biogen (BIIB) to develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to 9 additional neurological disease targets. Under the terms of the agreement, Biogen will pay Sangamo $350M upfront, inclusive of a license fee and equity investment, and Sangamo is eligible to receive up to $2.37B in future milestones.

Sangamo also has a partnership with Pfizer and Takeda (NYSE:TAK) to develop and evaluate ZFP-TFs. The company is working with Pfizer to evaluate ALS and frontotemporal lobar degeneration ("FTLD") that are linked to the mutations in the C9ORF72 gene. In the partnership with Takeda, the company is evaluating a preclinical program for Huntington's disease in which ZFP-TF is designed to differentially down-regulate the mutated disease-causing huntingtin gene ("HTT gene") while preserving the expression of the normal version of the gene.

As of 31 December, 2019, cash and equivalents on hand was $385M. The amount is excluding the $350M injection from the collaboration with Biogen, and when factored in, cash on hand should comfortably be in the range of high $600-700M. This should give them a comfortable runway to fund all operations well into 2021, an important point given that the recent stock market crash which limits any secondary offering options.

Impressively, the company has managed to strike several high-profile partnerships with 5 global biotech/big pharma companies. Such partnerships not only validate Sangamo's technology and capabilities, but they also provide future avenues of funding with as much as $6.34B royalties on net product sales and potential milestone payments due to the company.

Figure 1 Sangamo Therapeutics' Partnerships (Source)

In terms of competition, the company competes with several players, particularly in the cell and gene therapy space. bluebird bio has more advanced programs in both TDT and SCD and, to date, has shown much better efficacy. There are also other companies such as CRISPR Therapeutics (CRSP) that are using an alternative gene-editing method, CRISPR/Cas9 in gene therapy. Other companies such as Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are also developing CRISPR/Cas9 for treatments in TDT and SCD, although it must be noted that these are not their lead programs.

In terms of allogeneic CAR-T, there are more established players such as Allogene Therapeutics (ALLO), Cellectis (CLLS), and Precision Biosciences (DTIL). The main difference among these companies is primarily the choice of gene-editing tools with Allogene and Cellectis using TALEN while Precision is using ARCUS. All these companies are, currently, in a similar stage of clinical development.

In addition to healthy donors derived allogeneic therapies, Fate Therapeutics (FATE) is developing allogeneic therapies from induced pluripotent stem cells ("iPSCs") as a renewable cell source. The advantage of this is that product consistency and potency will be improved, and the manufacturing process will be akin to the well-established biologics where they are produced from a single cell line. It is notable to note that Allogene is also investigating using iPSCs as a renewable cell source. Also, Atara Biotherapeutics (ATRA) is developing an Epstein-Barr Virus ("EBV")-based allogeneic T cell therapy platform. Their lead program is in Phase 3 and a BLA filing is expected by the second half of the year. That should put them in the lead position of commercializing an allogeneic T cell therapy and the company is gradually moving into allogeneic CAR-T space as well.

Sangamo is, currently, trading at a market cap of around $700M, which is almost as much as its cash position. While its cash position will eventually deplete to fund operations and clinical trials, the current valuation means that there is also no value for its technology and intellectual position. I consider it a good time to take up a small position in Sangamo, especially if investors have a time horizon of at least a year to weather the COVID-19 black swan event and wait for further clinical updates from the company.

It must be cautioned though that investing in clinical-stage biotech can be extremely risky, given the binary nature of the field. This is especially so, given the market turmoil from the COVID-19 pandemic. The pandemic has also led to several countries announcing lockdowns, which have disrupted supply chain and operations. Several clinical trials have already been delayed globally and this may impact Sangamo negatively, as their cash burn will continue even if clinical trials are delayed.

Disclosure: I am/we are long ATRA, BLUE. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

More:

Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position - Seeking Alpha

Oscar Saxelby-Lee gets ‘super cells’ after having stem cell transplant from dad to fight off cancer – Ledbury Reporter

Posted on by

A SIX-year-old boy has received his super cells after having a stem cell transplant to fight off cancer.

Oscar Saxelby-Lee received his transplant yesterday (March 13) from his dad, Jamie Lee, who donated his cells to his little boy.

The Hand in Hand for Oscar Facebook page announced the heart-warming news: May these super cells be the beginning of something special just like you Ozzy Bear. We hope this gift will allow you a brand-new start to good health and end the monstrous ordeals you have been faced with. You will always have us by your side, hoping, praying and fighting for the brighter future you so very much deserve.

The emotive post continued: Daddy will always be with you, both inside and out now. How amazing is that. And how utterly amazing are you. You are so so close baby, keep going. Now for the difficult part of growing them and keeping him stable, but hes got this."

Oscar experienced a few slight implications during the transplant due to a reaction, but his parents have assured he is safe and is doing well.

Oscar has been in Singapore with his parents, Olivia Saxelby and Mr Lee, receiving CAR-T therapy after the community backed their appeal to raise 500,000 to afford the life-saving treatment. This is specialised therapy, which is only available in Singapore, to combat his T-cell acute lymphoblastic leukaemia. The young Worcester boy underwent a stem cell transplant last May after a search for a donor which saw thousands across the country to sign-up to a register in a bid to help.

The Worcester News previously reported that Oscar's parents were appealing for blood donations because there's a shortage due to less people donating due to the coronavirus. However, an NHS Blood and Transplant spokesman said blood stock levels are good.

The spokesman said: Our stock levels are good and we dont believe weve seen any effect on appointments. Were asking donors to keep donating as normal and to follow the latest travel and hygiene advice. Donation help us to keep stocks good so we are well prepared for every eventuality. Were regularly reviewing the situation and working closely with the government, Public Health England and the UKs other blood donation services. We're putting in place extra measures and safety is always our number one priority.

Read the original here:

Oscar Saxelby-Lee gets 'super cells' after having stem cell transplant from dad to fight off cancer - Ledbury Reporter

Mesothelioma Lawsuits and why you will need a Lawyer by your side – California Herald

Posted on by

Mesothelioma lawsuits have been upheld by courts in cases where workers have been exposed to asbestos and asbestos-containing materials without being alerted to the hazards of asbestos or given appropriate protection against asbestos exposure. Asbestos was a common construction material in the U.S. through the 1980s, at which time it became banned by the government. However, lawsuits have been successful because it has been shown that the hazards of asbestos exposure through inhalation were well known by asbestos manufacturers and companies using their products before that time.

Compensation for Mesothelioma

A mesothelioma lawsuit can be used to sue in order to get compensation for a mesothelioma sufferer. This compensation can be based on damages from lost income due to illness, medical expenses, pain and suffering and loss of consortium. Because the prognosis of life expectancy for mesothelioma sufferers is not very long, families are allowed to sue for this compensation as well. If a family member also is suffering from mesothelioma due to secondhand asbestos exposure, it is possible for them to sue for both parties.

Choosing a Mesothelioma Attorney

The best way to develop a successful mesothelioma lawsuit is to seek advice from a knowledgeable attorney who specializes in asbestos-related lawsuits. It is very important to work with an attorney that has a proven track record in this area because of the difficulty in successfully proving causes and fighting multinational corporations, companies as https://mesotheliomalawyers.com/ are specialized in this complex area. Because of the high latency period between the asbestos exposure and the onset of the disease, it is very hard to evince documentation that can prove causal linkages. Therefore, an in depth investigation should be done to gather as much evidence as possible on previous asbestos exposure history. Both the manufacturing companies who produced asbestos and asbestos-containing products and employers who exposed their workers to asbestos can be included in the lawsuit.

Mesothelioma Trust Funds

Sometimes, asbestos-related companies that are sued have filed for bankruptcy, and a part of the bankruptcy court proceedings has required that a compensation trust fund be created to help settle damages for those with asbestos-related illnesses as a result of their products. A capable attorney can help settle those claims and get compensation for a mesothelioma patient quickly.

Financial Assistance for Mesothelioma

If you are an individual who is suffering from mesothelioma, it is very important to keep detailed financial records and medical expense records in order to make compensation claims and get properly compensated. It is also important to provide proof of asbestos exposure, which can be difficult to do, because decades often elapse between the time of original asbestos exposure and the first symptoms. A reputable attorney specializing in mesothelioma claims can help with all of these issues, and potential plaintiffs should be aware that reputable attorneys specializing in asbestos-related lawsuits only take cases on a contingency basis, meaning that they will not get paid unless they recover money for the client. If you or someone you know has asbestos-related mesothelioma, please do not hesitate to get in touch if you would like to get more information on mesothelioma lawsuits.

The rest is here:

Mesothelioma Lawsuits and why you will need a Lawyer by your side - California Herald

Missouri US Navy Veterans Lung Cancer Advocate Urges a Navy Veteran or Person with Lung Cancer in Missouri Who Had Asbestos Exposure to Call for…

Posted on by

(MENAFN - EIN Presswire) "To get the compensation job done for a Navy Veteran or person with asbestos exposure lung cancer in Missouri the Advocate has endorsed the lawyers at Karst von Oiste-KVO. Missouri US Navy Veterans Lung Cancer Advocate

KANSAS CITY, MISSOURI, USA, March 25, 2020 / EINPresswire.com / -- The Missouri US Navy Veterans Lung Cancer Advocate is urging a Navy Veteran, a skilled trades worker, a manufacturing worker or a power plant worker who now has lung cancer to call them anytime at 800-714-0303 if they had significant exposure to asbestos decades ago in the navy or at work. Even if the Veteran or person smoked cigarettes there can be significant compensation for people like this. Most people like this are not aware the $30 billion dollar asbestos trust funds were set for up people with asbestos exposure lung cancer-not just mesothelioma as the Advocate would be happy to discuss anytime at 800-714-0303. The typical person the Advocate is trying to identify is over 60 years old. https://Missouri.USNavyLungCancer.Com

To get the financial compensation work done for a Navy Veteran or person with asbestos exposure lung cancer in Missouri the Missouri US Navy Veterans Lung Cancer Advocate has endorsed the lawyers at Karst von Oiste-KVO. The remarkable attorneys at the KVO law firm are responsible for over billion dollars in financial compensation for people with asbestos exposure lung cancer and mesothelioma. For direct access to the amazing lawyers at the law firm of Karst von Oiste-KVO please call anytime at 800-714-0303." http://www.karstvonoiste.com/

The Missouri US Navy Veterans Lung Cancer Advocate is offering to assist a Navy Veteran or person with asbestos exposure lung cancer in Missouri organize the how, where and when they were exposed to asbestos. They call this free service the 'list' and it is this vital information that becomes the foundation for a compensation claim as the would be happy to explain at 800-714-0303. https://Missouri.USNavyLungCancer.Com

The Missouri US Navy Veterans Lung Cancer Advocate's free services are available to people with asbestos exposure lung cancer or mesothelioma in Kansas City, St. Louis, Independence, Columbia, Lee's Summit, O'Fallon, St. Joseph or anywhere in Missouri. https://Missouri.USNavyLungCancer.Com

High-risk work groups for exposure to asbestos in Missouri include Veterans of the US Navy, civilian workers at Whiteman Air Force base, power plant workers, factory workers, public utility workers, plumbers, welders, industrial workers, electricians, auto mechanics, machinists, and construction workers. Typically, the exposure to asbestos occurred in the 1950's, 1960's, 1970's, or 1980's. http://www.karstvonoiste.com/

According to the American Cancer Society for nonsmokers who have been exposed to asbestos in their workplace the risk of lung cancer is five times that of unexposed workers. https://www.cdc.gov/cancer/lung/statistics/index.htm .

The US Navy Veterans Lung Cancer Advocate says, "If your husband, dad, coworker or neighbor has just been diagnosed with lung cancer and you know they had significant exposure to asbestos in the navy, at a shipyard or while working at a factory, at power plant, public utility, or as a plumber, electrician welder, mechanic or any kind of skilled trades group in any state please have them call us anytime at 800-714-0303. Most people like this never get compensated-even though the asbestos trust funds were set up for them too. We are trying to change this sad fact." https://USNavyLungCancer.Com

States with the highest incidence of lung cancer include Kentucky, West Virginia, Maine, Tennessee, Mississippi, Ohio, Indiana, Louisiana, Arkansas, Missouri, North Carolina, Rhode Island, Alabama, and Delaware. http://www.karstvonoiste.com/

For more information about asbestos exposure please visit the NIH's website on this topic: https://www.cancer.gov/about-cancer/causes-prevention/risk/substances/asbestos/asbestos-fact-sheet .

Michael ThomasMissouri US Navy Veterans Lung Cancer Advocate+1 800-714-0303email us here

MENAFN2503202000703196ID1099910464

EIN Presswire publishes and distributes press releases worldwide for small and mid-sized companies both public and private. Specializing in industry and business, topic categories range from agriculture and aviation to pharma and technology. The company was founded in 1995.

Original post:

Missouri US Navy Veterans Lung Cancer Advocate Urges a Navy Veteran or Person with Lung Cancer in Missouri Who Had Asbestos Exposure to Call for...

Universities Space Research Association’s Adam Goldstein Named Co-Investigator on NASA’s Recently Elected Proposed Mission on LargE Area burst…

Posted on by

COLUMBIA, Md. and WASHINGTON, March 25, 2020 /PRNewswire/ -- NASAScience Mission Directorate recently selected four Small Explorer (SMEX) mission concepts that would study cosmic explosions and the debris they leave behind, as well as monitor how nearby stellar flares may affect the atmospheres of orbiting planets. Among these is the LargE Area burst Polarimeter (LEAP) concept led by Principal Investigator Mark McConnell at the University of New Hampshire in Durham and Director of R&D at the Southwest Research Institute.The mission is being managed by NASA's Marshall Space Flight Center. One of the Co-Investigators on the project is Adam Goldstein of Universities Space Research Association (USRA) Science and Technology Institute in Huntsville, Alabama.

"These promising proposals under the Explorers Program bring out some of the most creative, innovative ways to help uncover the secrets of the universe," said Thomas Zurbuchen, associate administrator of the agency's Science Mission Directorate in Washington. "From studying stars and planets outside our solar system to seeking answers to the largest cosmic mysteries, I look forward to the breakthrough science from these modest size missions."

The LargE Area Polarimeter (LEAP) mission would be an instrument mounted as an external payload to the International Space Station, and its primary mission is to study the polarization of gamma rays from gamma-ray bursts (GRBs). GRBs are the most energetic explosions in the universe and are highly-relativistic jets of material ejected from the core-collapse of massive stars or when two neutron stars collide. An instrument capable of measuring the polarization of the GRB radiation has been long-desired in the community, since it could answer several open questions about the jet physics and the underlying processes that produce the jets. Specifically, measuring the polarization could inform us about the magnetic field strengths present in these systems during core-collapse or collision; it could tell whether the jet itself mostly contains matter moving at very near the speed of light or contains a lot of radiation; and it could also indicate how the matter in the jet is converted to the gamma-rays that we observe.

USRA's Adam Goldstein stated, "LEAP is an exciting project to be involved in because it promises to advance the study of GRBs and our understanding of high-energy astrophysics.GRBs have been studied for several decades, and yet there are still many open questions about their exact nature.LEAP could help answer a number of those."

Mark McConnell, the Principal Investigator, stated, "LEAP represents the culmination of many years of work to make some extremely important measurements. Not only do we have the right instrument for the task, but we also have been very successful in putting together a team of researchers who represent some of the foremost researchers in the study of Gamma Ray Bursts. We are thrilled with the prospects for the LEAP project."

The LEAP instrument is composed of gamma-ray scintillators coupled to photo-multiplier tubes, together creating detectors that owe heritage to both the current Fermi Gamma-ray Burst Monitor (GBM) and the previous Burst and Transient Source Experiment (BATSE) onboard the Compton Gamma-ray Observatory. Unlike GBM and BATSE, however, LEAP's unique arrangement of the detectors will allow it to measure the polarization of the gamma-rays that neither of the previous instrument had the capability to observe. Additionally, its very large observing area, several times that of GBM, will make it sensitive to detecting many GRBs, so GRB polarization could be measured for potentially hundreds of GRBs, allowing for a population analysis.

The selected missions are provided an opportunity to improve their proposed mission concept during an extended phase-A -- until 2021. NASA intends to select two of the four proposed mission concepts at that time for further development and launch in 2025.

Ghassem Asrar, Senior Vice President of Science at USRA noted, "We are thrilled to see USRA scientists supporting one of proposed SMEX mission concepts.What is also special about the LEAP Mission of Opportunity as an attached payload is that it will take full advantage of the International Space Station."LEAP will also complement NASA's Imaging X-ray Polarimetry Explorer (IXPE), scheduled to launch in 2021.

USRA, in partnership with Marshall Space Flight Center will take part in the awarded concept study to develop a final report on the ability of LEAP to achieve its proposed science. It is expected that in 2021, NASA will select the final mission concepts, and if LEAP is one of the missions chosen, it will be built and is expected to be operational in 2025.

About USRAFounded in 1969, under the auspices of the National Academy of Sciences at the request of the U.S. Government, the Universities Space Research Association (USRA) is a nonprofit corporation chartered to advance space-related science, technology and engineering. USRA operates scientific institutes and facilities, and conducts other major research and educational programs, under Federal funding. USRA engages the university community and employs in-house scientific leadership, innovative research and development, and project management expertise. More information about USRA is available at http://www.usra.edu.

About the Explorers ProgramManaged by Goddard, this is the oldest continuous NASA program designed to provide frequent, low-cost access to space using principal investigator-led space science investigations relevant to the Science Mission Directorate's astrophysics and heliophysics programs. Since the launch in 1958 of Explorer 1, which discovered Earth's radiation belts, the Explorers Program has launched more than 90 missions, including the Uhuruand Cosmic Background Explorer (COBE)missions that led to Nobel Prizes for their investigators. For information about the Explorers Program visit: https://explorers.gsfc.nasa.gov/index.html

PR Contact:Suraiya Farukhi, Ph.D.sfarukhi@usra.edu443-812-6945

Read the original post:

Universities Space Research Association's Adam Goldstein Named Co-Investigator on NASA's Recently Elected Proposed Mission on LargE Area burst...

The Mystery of Supermassive Black Hole Formation – AZoQuantum

Posted on by

Written by AZoQuantumMar 24 2020

Supermassive black holes are billions of times bigger than the Sun, but how is this possible? According to recent observations, these space giants already existed when the Universe was just 800 million years old and is currently 14 billion years old.

The emergence of these celestial giants in such a brief time poses a real scientific dilemma to astrophysicists, raising significant questions on the present knowledge relating to the formation of these cosmic bodies.

A new article, authored by Scuola Internazionale Superiore di Studi Avanzati (SISSA) PhD student Lumen Boco and his supervisor Andrea Lapi and recently published in The Astrophysical Journal, provides a potential explanation to this tricky problem.

Based on an original model conceptualized by Trieste researchers, the study recommends an extremely rapid formation process during the preliminary phases of the formation of the giant black holes, which, so far, were believed to be slower.

The study results mathematically showed that supermassive black holes could possibly exist in the young Universe and reconciled the timing needed for their development with the limitations imposed by the Cosmos age.

Thanks to upcoming gravitational wave detectors such as LISA and Einstein Telescope, the validity of this concept can be completely confirmed, while this was also tested in a number of rudimentary aspects using the present Advanced LIGO/Virgo system.

The researchers began their analysis with a piece of familiar observational proofthe development of giant black holes that takes place in the core regions of galaxies, progenitors of the present elliptical galaxies, which had an extremely high concentration gas and in which the star formation was very strong.

The biggest stars live a short time and very quickly evolve into stellar black holes, as large as several scores of solar masses; they are small, but many form in these galaxies, stated Boco and Lapi.

The duo further explained that the thick gas surrounding the black holes has a very strong definitive effect of dynamic friction and makes them to move quite rapidly to the core of the galaxy. Most of the various black holes that approach the core regions combine and produce the giant black hole seed.

According to classical theories, a supermassive black hole grows at the centre of a galaxy capturing the surrounding matter, principally gas, growing it on itself and finally devouring it at a rhythm which is proportional to its mass.

Lumen Boco, PhD Student, and Andrea Lapi, Supervisor and Coordinator, The Astrophysics and Cosmology Group, SISSA

Boco and Lapi continued, For this reason, during the initial phases of its development, when the mass of the black hole is small, the growth is very slow. To the extent that, according to the calculations, to reach the mass observed, billions of times that of the Sun, a very long time would be required, even greater than the age of the young Universe.

But the researchers study revealed that things could go relatively faster than that.

Our numerical calculations show that the process of dynamic migration and fusion of stellar black holes can make the supermassive black hole seed reach a mass of between 10,000 and 100,000 times that of the Sun in just 50-100 million years, added the researchers.

At this juncture, the scientists stated that the growth of the central black hole according to the aforementioned direct accretion of gas, envisaged by the standard theory, will become very fast, because the quantity of gas it will succeed in attracting and absorbing will become immense, and predominant on the process we propose.

Nevertheless, precisely the fact of starting from such a big seed as envisaged by our mechanism speeds up the global growth of the supermassive black hole and allows its formation, also in the Young Universe. In short, in light of this theory, we can state that 800 million years after the Big Bang the supermassive black holes could already populate the Cosmos.

Lumen Boco, PhD Student, and Andrea Lapi, Supervisor and Coordinator, The Astrophysics and Cosmology Group, SISSA

The study, apart from describing the model and illustrating its efficacy, also suggests a way for testing it: The fusion of numerous stellar black holes with the seed of the supermassive black hole at the centre will produce gravitational waves which we expect to see and study with current and future detectors, the scientists explained.

Specifically, the gravitational waves released in the preliminary phaseswhen the central black hole seed is still smallcan be identified using the existing detectors such as Advanced LIGO/Virgo and fully definable by the upcoming Einstein Telescope.

The resultant development phases of the giant black hole can possibly be analyzed due to the upcoming detector LISA, which will be introduced in space around 2034.

In this manner, the process we propose can be validated in its different phases, in a complementary way, by future gravitational wave detectors, explained Boco and Lapi.

This research shows how the students and researchers of our group are fully approaching the new frontier of gravitational waves and multi-messenger astronomy. In particular, our main goal will be to develop theoretical models, like that devised in this case, which serve to capitalise on the information originating from the experiments of current and future gravitational waves, thereby hopefully providing solutions for unresolved issues connected with astrophysics, cosmology and fundamental physics.

Andrea Lapi, Supervisor and Coordinator, The Astrophysics and Cosmology Group, SISSA

Source: https://www.sissa.it/

Read the rest here:

The Mystery of Supermassive Black Hole Formation - AZoQuantum

Mobile astronomy: Put the Milky Way in your pocket with ‘Our Galaxy’ smartphone app – Space.com

Posted on by

From time to time at star parties, I encountered someone who isn't very impressed with the dim, fuzzy object I'm showing them through my telescope. But once I explain what the object is, how far away it is, and how it connects to our place in the galaxy and the wider universe beyond, it sparks their imagination and they look at it again with renewed interest and appreciation. A new fun and educational app called Our Galaxy will let anyone learn about our place in the cosmos, and feel that sense of wonder.

In addition to the obvious bright planets and stars, the night sky is sprinkled with star clusters, nebulas, and distant galaxies, many of which are revealed by looking through binoculars and backyard telescopes. Astronomers refer to those exotic objects as deep-sky objects. Their positions in the sky aren't completely random. Star clusters and nebulas populate the spiral arms of our home galaxy, the Milky Way with more of them occurring closer to the center of the galaxy and fewer of them appearing along its outer rim. Their locations in the sky allow astronomers to trace out the structure and dimensions of our galaxy, and to determine where new stars are being formed within it.

Related: Stunning photos of our Milky Way Galaxy (gallery)

Planetary nebulas are the corpses of stars not unlike our sun that reached the end of their lives. Those objects can appear anywhere in our sky because our sun sits within a 3-dimensional volume of space; surrounded by stars of all ages. Globular clusters are spherical, densely-packed collections of old stars that orbit our galaxy like bees around a hive so they tend to be found near the band of the Milky Way, but not inside it. Distant galaxies are sprinkled throughout the sky, but they can only be mapped and observed where our own galaxy's gas and dust don't block their distant light.

Bill Tschumy, one of the creators of the popular SkySafari app, has created the perfect tool to understand our place in the Universe. The Our Galaxy app for iOS and MacOS lets users visualize the locations and physical properties of deep-sky objects within and around our galaxy. The app is a relatively small download at less than 60 Mb. Once loaded on your iPhone, it puts a deep sky expert in your pocket and the larger display on an iPad really shows off its wealth of detailed imagery.

The Our Galaxy app can be operated in two modes that are enabled by tapping Galaxy or Sky on the app's toolbar. The toolbar also features icons to open the search menu and Views library, read a page of information about the selected object, toggle red-light night mode, open the app's settings menu and help. Two whimsical spaceship-shaped icons in the toolbar serve as zoom controls one flies you closer, the other flies you out.

Galaxy View presents a 3-dimensional model of our Milky Way's barred spiral form that you can tilt and rotate, and zoom in and out of. A single tap in the Settings Orientation menu lets you select preset orientations, such as an edge-on view and a face-on view. In the Center menu, you can choose to keep our sun in the center, or rotate around the galactic core or around a selected star or deep-sky object. Across the top of the screen are shown your distance from the selected object, and the field of view (FOV) being displayed in light-years.

Sky View draws a rectangular (orthographic) map of the entire sky as viewed from Earth. Sky coordinates in degrees are labelled around the perimeter of the map. The major stars and lines that form the constellations are plotted in white on a black background. The deep-sky objects are overlain using colored symbols. The map can be enlarged and panned around. Tapping a symbol shows its object's name. Plotting one or more categories of deep-sky objects on the map view illustrate how they can be used to define our galaxy's structure, or be completely independent of it all useful information for understanding how galaxies like ours are structured. A single tap switches between sky and galaxy view.

The app is highly configurable. You can decide whether to display labelled names next to the symbols, identify the various spiral arms of the galaxy, and show the Constellation Sectors the portions of the Milky Way that lie in the direction of certain constellations, such as Orion, Gemini or Cygnus.

To clean up the view, simply enter the settings menu and tap the remove options.

The app contains an extensive library of stars and objects. An object can be selected by typing its name or its designation into the search menu or by tapping its symbol on the screen. Multiple deep-sky objects can be displayed at the same time, as I describe below.

The app's powerful search menu allows you to type all or a portion of an object's name or designation, include or exclude object types, and limit the search to specific ranges of magnitude (brightness), distance, age, size and more. You can even search all constellations, or select a single constellation.

The list of results can then be displayed on the map or 3D model. It's especially interesting to see how the stars and deep-sky objects of a single constellation fall at vastly different distances from our sun.

The more you work with the app, the more you will learn about astronomy, astrophysics, and cosmology all presented using clear, understandable text and graphics.

The Views library is especially educational for understanding how various classes of objects populate the galaxy. Nine categories are offered: individual stars and OB Associations (hot, bright stars), open and globular clusters, various types of nebulas, galaxies, and our galaxy's structural components. There is also an entry for the list of well-known Messier objects. Each entry has an information icon to summon a description of that object class.

Tapping any category opens a sublist that allows you to select all members of the class, or sub-groups. For example, in the Diffuse Nebulae view, you can treat emission and reflection nebulas as separate groups, or combined, each type color-coded appropriately (with red for light emitted from hydrogen, blue for starlight scattered off dust, and green for both phenomena).

The Visibility menu contains sliders to plot galactic axes and to add wire mesh representations of the galaxy's central bulge, dark matter halo sphere, and more.

For cosmology buffs, the app contains 3D locations for hundreds of galaxies. Selecting the galaxy category and using "Galaxy view" puts you 92 billion light-years away from home. Manipulating the model shows how some galaxies concentrate in groups while others leave empty voids in the visible universe.

The Our Galaxy app will give you a true perspective on our place in space. Bill Tschumy has posted a YouTube video demonstration of the app here. Enjoy exploring the galaxy and, as always, keep looking up!

Chris Vaughan is an astronomy public outreach and education specialist at AstroGeo, a member of the Royal Astronomical Society of Canada, and an operator of the historic 74-inch (1.88-meter) David Dunlap Observatory telescope. You can reach him via email, and follow him on Twitter @astrogeoguy, as well as on Facebook and Tumblr. Follow SkySafari on Twitter @SkySafariAstro. Follow us on Twitter @Spacedotcom and on Facebook.

More:

Mobile astronomy: Put the Milky Way in your pocket with 'Our Galaxy' smartphone app - Space.com

The true impact of SpaceXs Starlink constellation on astronomy is coming into focus – The Verge

Posted on by

Ever since SpaceX launched its first batch of internet-beaming satellites last year, astronomers have watched with dread as the company continued to blast more spacecraft into orbit. Could this ballooning constellation of bright satellites fill the night sky with artificial light and muck up observations of the Universe for years to come? Now, new data is partially validating what many astronomers have feared since that first launch.

Up until now, people have been somewhat in the dark about the true impact of SpaceXs internet-from-space project called Starlink, which envisions nearly 12,000 of these satellites orbiting Earth. SpaceXs satellites are super bright compared to others, and astronomers have been worried that with so many luminous satellites in the sky, the odds of one passing in front of a telescope and obscuring an image will increase.

It turns out, some astronomers have reason to be concerned. Certain types of astronomy may be more negatively affected than others, one peer-reviewed study shows, particularly those kinds that scour large swaths of the sky over long periods of time looking for faint, faraway objects. That means scientists looking for distant objects beyond Neptune including the hunt for the mysterious Planet Nine might have trouble when Starlink is complete. Additionally, Starlink may be much more visible during twilight hours, or the first few hours of the night, which could be a major problem in the hunt for massive asteroids headed toward Earth. It depends on what science youre doing, and thats really what it comes down to, Jonathan McDowell, an astrophysicist at Harvard and spaceflight expert who wrote the study accepted by Astrophysical Journal Letters, tells The Verge.

Meanwhile, scientists are also learning if SpaceXs effort to mitigate the brightness of its satellites is actually going to work. The company coated one of its satellites in an attempt to make it appear less visible in the sky. Now, the first observations of that satellite are being published, and the coating is working but it might not be enough to make everyone happy. It doesnt solve the issue, Jeremy Tregloan-Reed, a researcher at the University of Antofagasta and lead author on the study, which is undergoing peer review at Astronomy and Astrophysics Letters, tells The Verge. But it shows that SpaceX has taken on board astronomers concerns, and it does appear to be trying to solve the situation.

For astronomers, light is everything. Observing celestial objects in different wavelengths of light is the best method we have for exploring the Universe. Thats why adding artificial light to the sky freaks out so many scientists. Some astronomers take long-exposure images of the sky, gathering as much light as possible from distant objects and when a bright satellite reflecting light from the Sun passes overhead, it can leave a long white streak that ruins the picture.

Of course, the sky is a big canvas, and one tiny satellite isnt going to be a major headache. A host of factors dictate exactly how and when satellites will be a problem. A satellites size, shape, height, and path around Earth all affect exactly how much light it reflects from the Sun and where people will see it the most. Meanwhile, the time of year and the time of night determine how much sunlight is shining on a satellite at any given moment.

To figure out Starlinks exact impression on the night, McDowell made a comprehensive simulation based on what we know about where all of the Starlink satellites are going. Ahead of launching its constellation, SpaceX had to file multiple requests with the Federal Communications Commission, detailing where the company planned to send all of its spacecraft. Using that information, McDowell came up with a snapshot of which areas will see the most satellites overhead and what times of night will be the worst for observations.

In the more northern and southern latitudes, Starlink satellites will dominate the horizon during the first and last few hours of the night. In the summertime, itll be much worse, with hundreds of satellites visible for those in rural areas away from city light pollution. Where I live in [Boston], I can see the planes hovering over Logan [Airport] on the horizon, says McDowell. Thats what it will look like, but itll be satellites and itll be a lot of them. SpaceX declined to comment for this story.

While people living in cities and towns wont really notice, this spells bad news for those hunting really distant faint objects using long exposures. The longer that you have the shutter open for, the more that youre likely to have an observation impeded by one of these streaks that are quite bright, Michele Bannister, a planetary astronomer at the University of Canterbury in New Zealand who helped McDowell with his research, tells The Verge. That means those hunting Planet Nine and objects at the edge of the Solar System have some cause for alarm.

Additionally, asteroid hunters are going to be extra affected by this constellation, says McDowell. Theyre really hosed, because they need to look at twilight, he says. Scientists looking for asteroids orbiting near Earth often look for these objects near the Sun; they observe just after sunset when they can see the part of the sky near the Sun thats too bright to see during the day. Thats where the problem with illuminated Starlink satellites is the worst, he says. Even from regular 30-degree latitude observatories, theyre going to have serious problems.

As for what that means for these astronomy fields, one obvious concern is that a potentially hazardous asteroid could go unnoticed until its too late to act appropriately. Its also possible observers will have to take expensive countermeasures to get the kinds of images they want. It may mean you have to observe twice as long, if you have to throw away half your data, says McDowell. So thats expensive. Or you may need to make changes to your telescope design, to stop reflections from a satellite.

The silver lining here, at least, is that McDowells study found that Starlink may not really have a big effect on a lot of other astronomers work, especially those who only look at small slices of the night sky for certain periods of time. But his work does fly in the face of what SpaceX CEO Elon Musk has said about Starlink and its astronomy repercussions. I am confident that we will not cause any impact whatsoever in astronomical discoveries. Zero, Musk said during a space conference at the beginning of March. Thats my prediction. And well take corrective action if its above zero.

Despite Musks brazen proclamation, the truth is SpaceX has already taken some corrective action, but new research shows it may not be enough to silence all of the companys critics.

On its third Starlink launch in January, SpaceX included a satellite that had been painted with an experimental coating, meant to darken the spacecrafts reflectivity. Nicknamed DarkSat, the spacecraft has been of particular interest to amateur satellite trackers. Various observatories have taken images of DarkSat as its passed overhead to gauge just how much fainter it appears compared to its cohort.

The answer, it seems, is that DarkSat is indeed darker but only slightly. Once it reached its final orbit, the satellite appeared 55 percent fainter compared to another bright Starlink satellite, according to Tregloan-Reeds study. Thats based on the initial observations he made using a telescope at the Ckoirama Observatory in Chile. The DarkSat coating does push the satellite beyond being able to be seen with the naked eye, says Tregloan-Reed.

Thats a big reduction, but 55 percent may not be enough for some observatories. The Vera Rubin Observatory in Chile is still under construction, but it has the massive task of surveying the entire night sky. Its going to be able to give us the history of the Solar system in absolutely intricate and amazing detail, says Bannister of the survey. And I think thats definitely something that is under threat. People at the observatory have estimated that the Starlink satellites would need to be even fainter than DarkSat in order to truly stay out of the way and not saturate the images gathered.

The good news is that SpaceX has hinted that more extreme countermeasures may be on their way. During its latest launch, a SpaceX employee noted that while the coated satellite showed a notable reduction in brightness, a future Starlink satellite may be equipped with a sunshade to further reduce reflectivity. We have a couple other ideas that we think could reduce the reflectivity even further, the most promising being a sunshade that would operate in the same way as a patio umbrella, or a sun visor but for the satellite, Jessica Anderson, a lead manufacturing engineer at SpaceX, said during the live stream.

Tregloan-Reed says hes hopeful about some kind of shade. If that was to work then in theory it would block out the sunlight completely, he says.

Still, that doesnt solve every single astronomy problem because even a darkened satellite can still be a nuisance. Astronomers searching for planets beyond our Solar System, for instance, often take very sensitive measurements of distant stars, looking for dips in their brightness that might indicate a foreign planet passing by. If a satellite, even a dark one, were to pass in front of a star someone was observing, it could throw off the search for these alien worlds.

No matter what, it seems that a giant constellation is going to have some kind of negative impact on someone it cant be helped. And looking at the big picture, SpaceX isnt alone in its attempt to create a mega-constellation of satellites. The company just gets the most attention because its proposing the largest number of spacecraft, and its vehicles are big, bright, and lower in the sky compared to other proposed constellations. Others like OneWeb and Amazon want to also fill the sky with internet-beaming vehicles.

Such a large influx of artificial bright spots is really the heart of the issue. I understand the importance of Starlink; I can see the benefits of worldwide internet, says Tregloan-Reed. Its just the sheer numbers that are worrying me.

View original post here:

The true impact of SpaceXs Starlink constellation on astronomy is coming into focus - The Verge

An Interview With Matthew Mercer About The Explorers Guide To Wildemount – Forbes

Posted on by

The crossover effort between Dungeons & Dragons and Critical Role is here,

Matthew Mercer and his show Critical Role has a profound impact on Dungeons & Dragons. Millions of new players have tried D&D after watching Mercer and his crew of nerdy voice actors play through an epic story. The Critical Role crew have played live shows across the world and Mercer has been Dungeon Master for notable people from Vin Diesel to Stephen Colbert. They have also expanded beyond livestreaming content into shows for Amazon Prime. This month, Matt Mercer gets to cross another item off his bucket list; author of an official D&D book from Wizards of the Coast called Explorers Guide to Wildemount.

I was caught off guard because Wizards contacted us, said Mercer, I had been brought in to contribute on a couple books which was a really, really cool experience, but I never expected it at this level. I had done one book with Green Ronin, the TalDorei guide which was an awesome learning experience, a time consuming experience where I learned a lot through that process with them. If it wasnt with Wizards in an opportunity like this I probably would have held off because of how crazy life has been.

The book details the continent of Wildemount on the world of Exandria where the campaigns of Critical Role are set. Wildemount is the setting of the current episodes on the show. The book includes details on the setting, spells, character options and plenty of information fans of the show are looking to devour.

Ever since I finished [the TalDorei guide] my world building and note taking had taken more of a formal approach, said Mercer, so, thankfully when this came around, I had more thorough notes and ideas that didnt completely need an overhaul. Of course, I only developed enough to touch on the campaign that I was running. The process from that point became How do I take the things that I already have established or partially fleshed out into an entirely suitable form? and What ideas do I have beyond those and how do I flesh them out in an equally exciting way?

Even D&D fans who are not deep into the show will find some interesting ideas contained within. The Heroic Chronicle charts offer players a way to pull together a character with backstories that link their characters together and to the setting without wandering through a few awkward sessions of getting to know characters. Mercers world also offers some unusual magic schools that draw their power from scientific sources such as gravity, time and probability.

A lot of that stems from a love of quantum physics and astrophysics growing up, said Mercer, Ive always had a love of those weird esoteric elements of theoretical science. I came up with the Kyrn Dynasty before we started the second campaign as a way to renovate the class and present these ideas in an innovative way in a classic D&D setting. As part of that religious scenario, I thought about what kind of magic in the world hadnt really been touched on and what magic intrigued me. I wanted to look at how gravity and probably affects you from a theoretically standpoint. How could I adapt that under an umbrella of magic that was unique to this world?

Mercer took a hand in every element of the book from story elements to mechanical write ups. He was joined by veteran D&D authors James J. Haeck, James Introcaso and Chris Lockey with development handled by Jeremy Crawford, Dan Dillon, Ben Petrisor and Kate Welch.

I began doing some home brewed class mechanic stuff on DMs Guild years ago and found that I really enjoyed it, said Mercer. Getting better at it as time goes on has been a real thrill for me. Being able to write narrative world building elements is a safer space because nobody can argue with it. With player facing mechanics theres a much more intense level of scrutiny, so its a bigger challenge to create. I really enjoy monster design because I make a lot of monsters for Critical Role because we have such a large party of powerful players. Its become a secondary hobby of mine to create weird, interesting, dynamic battles for my players.

Explorers Guide to Wildemount is available on Amazon or from Friendly Local Game Stores around the world.

Read the original post:

An Interview With Matthew Mercer About The Explorers Guide To Wildemount - Forbes